TRIG3 — 30 mg

TRIG3 is a revolutionary, first-in-class triple-hormone-receptor agonist that simultaneously targets the Glucagon-like peptide-1 (GLP-1), Glucose-dependent Insulinotropic Polypeptide (GIP), and Glucagon (GCG) receptors. This unique unimolecular polypharmacology creates a synergistic metabolic effect: GLP-1 agonism suppresses appetite via central satiety pathways; GIP agonism enhances peripheral insulin sensitivity and lipid buffering; while Glucagon agonism directly increases resting energy expenditure, hepatic glycogenolysis, and thermogenesis. This triad results in profound, multi-faceted weight reduction and superior glycemic control, surpassing single or dual-receptor agonists. Research on Retatrutide is heavily focused on non-alcoholic steatohepatitis (NASH), severe obesity, and cardiovascular risk reduction. The 20 mg and 10 mg variants allow researchers to design dose-escalation and dose-response studies. It requires cold-chain management (-20°C) to preserve its complex tertiary structure.